Physician oriented

In diabetes care, “therapeutic inertia” refers to the failure to escalate or modify treatment when a patient’s glucose control is suboptimal. Even now — when newer, more effective treatments and monitoring tools are widely available — therapeutic inertia in diabetes remains a stubborn barrier. Providers often wait too long before …

by Guest Writer Richard Purcell
More than 100 million U.S. adults are now living with diabetes or prediabetes, according to the Centers for Disease Control and Prevention.1 This epidemic requires new healthcare models to deliver optimal, patient-focused, guideline-directed care to improve outcomes and reduce costs. The establishment of a new multispecialty Managed Services Organization (MSO) in Arizona spotlights the numerous benefits, to patients and providers alike, of providing end-to-end healthcare services and disease management solutions for complex diabetes.

New type 2 drug can be used as monotherapy.